James McCormick, DPM
Foot Surgery · Wakefield, RINPI 1972566644
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.7%), education and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Stryker at 50.7% of the total. Reporting peaked in 2024 at $1,477 and has fallen 98.8% since, to $18 in 2025.
Across 32 payments — averaging $110.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Kairos Surgical Inc$1K
- Bioventus LLC$183
- Misonix Inc$152
- Smith+Nephew$76
- Osiris Therapeutics Inc.$25
- plus $83 from 4 others
Across 1 payment — averaging $16,550 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Reddress LTD$17K
What the payments were for
- Travel & lodging$1,61146%
- Food & beverage$71620%
- Education$1,20034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 9 | $1,788 |
| Kairos Surgical Inc | 2 | $1,220 |
| Bioventus LLC | 6 | $183 |
| Misonix Inc | 6 | $152 |
| Smith+Nephew | 4 | $76 |
| Osiris Therapeutics Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Lifenet Health | 1 | $22 |
| Amgen | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROstep$1,605
How this compares
Too few foot surgery providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 52 | $1,220 |
| Terbinafine Hcl | 29 | $331 |
| Oxycodone Hcl | 54 | $214 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $174 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $145 |
| Meloxicam | 33 | $142 |
| Methylprednisolone | 19 | $122 |
| Mupirocin | 12 | $92 |
| Cephalexin | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Wakefield
- Eric BuchbaumWakefield$7K
- Thomas ManciniEast Greenwich$3K
- Louis SimeoneProvidence$1K
- Edmund DosremediosProvidence$1K
- Thomas HuottRiverside$929
- Mark EnanderPawtucket$269
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.